fda compounding semaglutide enforcement 2025 news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Troubling Findings in Study of

Switching from WeightWatchers GLP-1 does not mean starting over If you already use WeightWatchers, the useful habits transfer naturally: food awareness, weight logging, hydration, protein, activity, symptoms, and medication routines

Top Peptide Brands and Vendors Considered by HCS-Pharma HCS-Pharma evaluates a wide range of reputable peptide suppliers, including: Core Peptides Phoenix Pharmaceuticals GenScript Bachem Aapptec Peptides Other trusted US-based peptide companies These brands are recognized for consistently meeting or exceeding the highest standards in purity, transparency, and customer satisfaction

Here are recent blogs explaining the issues involved: Californians push back against proposed restrictions on glutathione and other alternative treatments Why compounding pharmacies matter and why you should care What is glutathione and why must we protect patient access to it

Thyroid 26 (1), 1133

Uses Here is a list of conditions that the Food and Drug Administration (FDA) has approved Vyvanse and Adderall to treat

G6PD in Red Blood Cell Metabolism In metabolic maps, G6PD is commonly referred to as the first enzyme of the hexose monophosphate shunt, or the pentose phosphate pathway ( Fig